Biophytis announces its participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR) Biophytis announces its participation in the International Conference on Frailty and Sarcopenia Research & Geroscience Task Force (ICFSR), taking place from March 12 to 14 in Toulouse. The International Conference on Frailty and Sarcopenia Research (ICFSR) is a leading annual…
“Live healthier longer” – Publication of a book on the medicine and science of longevity Biophytis announces the publication of a book written by Stanislas Veillet, CEO and co- founder of the company, together with René Lafont, Professor Emeritus at Sorbonne University and co- founder of Biophytis, and Jean Mariani, Professor and Director of the…
In an exclusive interview with Biotech Info (in French), Stanislas Veillet, CEO & co-founder of Biophytis, unveils the capital increase for Sarconeos (BIO101) targeting severe COVID-19 & sarcopenia. With Phase 3 trials in sight, shareholders are invited to join this pivotal phase. Read here
Biophytis obtains FDA Authorization to initiate the SARA-31 phase 3 study in sarcopenia Biophytis announced that it has received FDA (Food and Drug Administration) authorization to launch its SARA-31 study in the US, the first ever phase 3 study in sarcopenia. This authorization complements the positive opinion obtained this summer from the Belgian authorities to…
Biophytis receives a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe Biophytis announced that it has received a positive opinion from Belgian authorities to conduct its SARA-31 program, which will be the first phase 3 study ever launched in sarcopenia. The launch of the Phase 3 program follows the promising results…